INVESTOR RESOURCES
iCHOR COMPANY INFORMATION, NEWS & PRESENTATIONS
Corporate Overview
iCHOR was founded by Interventional Radiologist Dr. Troy Long and industry veteran Tim Blair who saw an opportunity to develop new technologies to address the large unmet needs in treating peripheral vascular occlusions. They have devised a technology that has converted the tried and proven Fogarty balloon sweep method from an open surgery to a minimally-invasive endovascular procedure. The overall corporate objective is to focus on creating a one-size-fits-all system that replicates successful parameters of surgical clot removal while addressing the shortcomings of current therapeutic options. The Team’s long-term vision is for the iSWEEP system to become the standard of care and first-line therapy for treating peripheral vascular occlusions, increasing clinical flexibility while delivering improved outcomes at a lower cost. The iCHOR team consists of a group of experienced multi-disciplinary members, including entrepreneurs, executives, physicians, regulatory experts, and engineers. Together, we bring a broad range of experience in the development, regulatory approval, and commercialization of medical devices in the peripheral vascular space.
iCHOR at LSI '24
Medline Review Articles
The Latest News
Understanding the Total Cost of Procedures for Thrombectomies
Hospitals routinely underestimate the true cost of thrombectomy because they focus on device price instead of the full episode of care. This article argues for a broader, “total cost” view that captures all direct and indirect drivers of financial performance around clot-removal procedures. Why “total cost” matters Most thrombectomy cost discussions center on device list price, yet materials are only…
iCHOR Vascular, Simply Taking a Proven Surgical Fogarty Sweep into the Endovascular Labs
What inspired the creation of Ichor Vascular and the development of its core technology platform? The creation of Ichor Vascular was inspired by a clear clinical gap the founders observed while working with multiple thrombectomy technologies in pre-clinical labs. During this process, they evaluated aspiration, metal cages, maceration, and other clot-removal tools, yet consistently found that the decades-old Fogarty balloon…